EUVIMEDEUVIMED entdecken
Crossref

Hyperparathyroidism in a Large Cohort of Chinese Patients With Tumor-induced Osteomalacia

Xiaolin Ni, Wei Liu, Dingding Zhang iD, Xiang Li, Yue Chi, Juan Feng, Chenxi Jin, Qianqian Pang, Yiyi Gong iD, Lijia Cui, Ruizhi Jiajue, Wei Yu und 13 weitere

The Journal of Clinical Endocrinology & Metabolism · 2023

DOI: 10.1210/clinem/dgac650 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Journal of Clinical Endocrinology & Metabolism, 2023. Verfasst von Xiaolin Ni und 24 weiteren Autor:innen. Beteiligte Einrichtung: Department of Endocrinology, Key Laboratory of Endocrinology, National Commission of Health, State Key Laboratory of Complex Severe and Rare Diseases…. Hauptthemen laut MEDLINE: Hyperparathyroidism, Secondary, Paraneoplastic Syndromes, Osteomalacia, Neoplasms. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 37 Literaturangaben. Gefördert von: National Natural Science Foundation of China, CAMS Innovation Fund for Medical Sciences, National Key R&D Program of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Context

Tumor-induced osteomalacia (TIO) is a rare paraneoplastic syndrome caused by excessive production of fibroblast growth factor 23 (FGF23) by a tumor. Hyperparathyroidism (HPT) including secondary HPT (SHPT) and tertiary HPT (THPT) in TIO patients, which is believed to be associated with phosphate supplementation, has not been well documented.

Objectives

To clarify the prevalence, clinical characteristics, and risk factors for HPT in a large cohort of Chinese patients with TIO in our hospital. Design, setting, and participants This retrospective study enrolled 202 patients with TIO. Main outcome measurements Occurrence of HPT in patients with TIO.

Results

HPT was observed in 91 patients (91/202, 45.1%): 84 patients (41.6%) with SHPT and 7 patients (3.5%) with THPT. All patients with THPT underwent parathyroidectomy and only 1 patient experienced recurrence. Compared with patients without HPT, patients with SHPT had longer disease duration, higher rate of phosphate and calcitriol supplementation, lower serum calcium, lower urine calcium excretion, and higher urine phosphate excretion. Compared with patients with SHPT, patients with THPT had even longer disease duration and a higher rate of phosphate and calcitriol supplementation. PTH levels showed positive correlation with intact FGF23 and 1,25-dihydroxyvitamin D levels, but not 25-hydroxy vitamin D level in patients with TIO. Multivariate logistic regression analysis showed that long disease duration and phosphate supplementation were independently associated with occurrence of HPT in patients with TIO. Further logistic regression analysis and restricted cubic spline model revealed dose-response relationship between cumulative dose of phosphate supplementation and PTH levels.

Conclusions

HPT is common in patients with TIO. To avoid the occurrence of HPT in patients with TIO, timely diagnosis and tumor resection is necessary and an excessive dose of phosphate supplementation is not suggested before surgery.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Hyperparathyroidism, SecondaryParaneoplastic SyndromesOsteomalaciaNeoplasmsHumansCalcitriolCalciumRetrospective StudiesEast Asian PeoplePhosphates

Stichwörter der Autor:innen

phosphate supplementationrisk factorssecondary hyperparathyroidismtertiary hyperparathyroidismtumor-induced osteomalacia

Substanzen

CalcitriolCalciumPhosphates

Autor:innen und Institutionen

  • Department of Endocrinology, Key Laboratory of Endocrinology, National Commission of Health, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Sc…
  • Medical Research Center, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Beijing 100730, China.
  • Department of Endocrinology and Metabolism, Renji Hospital, School of Medicine, Shanghai Jiaotong University, Shanghai 200127, China.
  • Department of Endocrinology, Beijing Tsinghua Changgung Hospital, School of Clinical Medicine, Tsinghua University, Beijing 102218, China.
  • Department of Radiology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Beijing 100730, China.
  • Department of Pathology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Beijing 100730, China.

ORCID-Profile: Dingding Zhang, Yiyi Gong, Mei Li, Yan Jiang, Weibo Xia

Förderung

  • National Natural Science Foundation of China
  • CAMS Innovation Fund for Medical Sciences
  • National Key R&D Program of China

Zitieren

APA

Ni, X., Liu, W., Zhang, D., Li, X., Chi, Y., Feng, J., Jin, C., Pang, Q., Gong, Y., Cui, L., Jiajue, R., Yu, W., Wu, H., Huo, L., Liu, Y., Jin, J., Zhou, X., Lv, W., Zhou, L., …, & Xia, W. (2023). Hyperparathyroidism in a Large Cohort of Chinese Patients With Tumor-induced Osteomalacia. The Journal of Clinical Endocrinology & Metabolism. https://doi.org/10.1210/clinem/dgac650

Vancouver

Ni X, Liu W, Zhang D, Li X, Chi Y, Feng J, et al. Hyperparathyroidism in a Large Cohort of Chinese Patients With Tumor-induced Osteomalacia. The Journal of Clinical Endocrinology & Metabolism. 2023. doi:10.1210/clinem/dgac650

BibTeX
@article{Ni2023,
  author = {Ni, Xiaolin and Liu, Wei and Zhang, Dingding and Li, Xiang and Chi, Yue and Feng, Juan and Jin, Chenxi and Pang, Qianqian and Gong, Yiyi and Cui, Lijia and Jiajue, Ruizhi and Yu, Wei and Wu, Huanwen and Huo, Li and Liu, Yong and Jin, Jin and Zhou, Xi and Lv, Wei and Zhou, Lian and Xia, Yu and Wang, Ou and Li, Mei and Xing, Xiaoping and Jiang, Yan and Xia, Weibo},
  title = {Hyperparathyroidism in a Large Cohort of Chinese Patients With Tumor-induced Osteomalacia},
  journal = {The Journal of Clinical Endocrinology & Metabolism},
  year = {2023},
  doi = {10.1210/clinem/dgac650}
}
Kostenlos starten →